Date published: 2025-10-25

1-800-457-3801

SCBT Portrait Logo
Seach Input

OR52N1 Inhibitors

OR52N1 inhibitors are a specialized class of chemical compounds designed to target the OR52N1 receptor, which is part of the olfactory receptor family within the G-protein-coupled receptor (GPCR) superfamily. Like other olfactory receptors, OR52N1 is traditionally associated with the detection of odorants, but its expression in non-olfactory tissues suggests it may have additional roles in various physiological processes. Inhibitors of OR52N1 function by binding to the receptor and blocking its interaction with natural ligands, thereby modulating the receptor's activity and downstream signaling pathways. The exact mechanisms by which OR52N1 inhibitors exert their effects depend on their molecular structure and how they interact with the receptor. These inhibitors are key tools for probing the biological functions of OR52N1, particularly in contexts outside of olfaction, where the receptor's role is less well understood. Chemically, OR52N1 inhibitors can vary significantly in their composition, reflecting differences in their binding affinities, selectivity, and modes of action. Some inhibitors may directly compete with endogenous ligands for binding to the active site of OR52N1, effectively blocking signal transduction. Others may act allosterically, binding to a different site on the receptor and causing conformational changes that reduce its activity. The design and development of these inhibitors often rely on detailed structural information about OR52N1, obtained through techniques such as X-ray crystallography, cryo-electron microscopy, and computational docking studies. This structural information is critical for identifying potential binding sites and optimizing the interactions between the inhibitor and the receptor. Research into OR52N1 inhibitors is focused on understanding how these compounds can specifically and effectively modulate the receptor's function, providing insights into the broader physiological roles of OR52N1. This involves not only the chemical optimization of these inhibitors but also extensive studies of their effects on cellular signaling pathways and the biological processes influenced by OR52N1.

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Trichostatin A

58880-19-6sc-3511
sc-3511A
sc-3511B
sc-3511C
sc-3511D
1 mg
5 mg
10 mg
25 mg
50 mg
$149.00
$470.00
$620.00
$1199.00
$2090.00
33
(3)

Trichostatin A may reduce OR52N1 expression by tightening chromatin structure around its promoter region, thus hindering access for transcriptional machinery.

5-Azacytidine

320-67-2sc-221003
500 mg
$280.00
4
(1)

As a cytidine analog, 5-Azacytidine could decrease OR52N1 expression by causing DNA demethylation, which can disrupt transcriptional control mechanisms at the gene's promoter.

Actinomycin D

50-76-0sc-200906
sc-200906A
sc-200906B
sc-200906C
sc-200906D
5 mg
25 mg
100 mg
1 g
10 g
$73.00
$238.00
$717.00
$2522.00
$21420.00
53
(3)

Actinomycin D may inhibit OR52N1 expression by intercalating into DNA, blocking RNA polymerase movement and subsequent transcription of the gene.

Mithramycin A

18378-89-7sc-200909
1 mg
$54.00
6
(1)

Mithramycin A can downregulate OR52N1 expression by binding to its promoter DNA sequences and obstructing the binding of essential transcription factors.

DRB

53-85-0sc-200581
sc-200581A
sc-200581B
sc-200581C
10 mg
50 mg
100 mg
250 mg
$42.00
$185.00
$310.00
$650.00
6
(1)

DRB might decrease OR52N1 expression by selectively inhibiting the transcription elongation process, which is critical for the synthesis of the full-length OR52N1 mRNA.

Camptothecin

7689-03-4sc-200871
sc-200871A
sc-200871B
50 mg
250 mg
100 mg
$57.00
$182.00
$92.00
21
(2)

By inhibiting topoisomerase I, Camptothecin could lead to DNA damage responses that decrease OR52N1 expression by triggering cell cycle arrest or activating DNA repair pathways.

Oxamflatin

151720-43-3sc-205960
sc-205960A
1 mg
5 mg
$148.00
$461.00
4
(1)

Oxamflatin may downregulate OR52N1 by preventing histone deacetylation, which could result in less accessible chromatin for genes like OR52N1, thereby reducing their expression.

α-Amanitin

23109-05-9sc-202440
sc-202440A
1 mg
5 mg
$260.00
$1029.00
26
(2)

α-Amanitin could inhibit OR52N1 expression by targeting RNA polymerase II and preventing the elongation of OR52N1 mRNA transcripts, leading to reduced mRNA abundance.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

Rapamycin (Sirolimus) could decrease OR52N1 protein levels by inhibiting mTOR, a pathway that promotes protein synthesis, including the translation of OR52N1 mRNA.

(±)-JQ1

1268524-69-1sc-472932
sc-472932A
5 mg
25 mg
$226.00
$846.00
1
(0)

JQ1 might downregulate OR52N1 by inhibiting BRD4, a member of the BET bromodomain family, which normally enhances transcription of certain genes.